The global coronary stents market size was estimated at USD 8.3 billion in 2024 and is projected to grow at a CAGR of 2.6% from 2025 to 2030. The increasing prevalence of coronary artery diseases (CAD) due to aging, poor diets, and sedentary lifestyles has heightened the demand for coronary stents. In September 2024, an article published in Biomedical and Environmental Sciences reported that cardiovascular disease (CVD) remains a leading health threat in China, exacerbated by an aging population and unhealthy lifestyles. Innovations in stent design, such as bioresorbable and drug-eluting stents, have improved their effectiveness and reduced complications, further driving market growth. Enhanced healthcare infrastructure and greater awareness of CAD treatments also contribute to more patients seeking stent-based interventions.
The rising number of people suffering from coronary artery diseases (CAD) due to factors like aging, unhealthy diets, sedentary lifestyles, and high-stress levels is a key driver. This has led to a greater demand for coronary stents as a common treatment option for patients with blocked or narrowed arteries. In October 2024, the CDC reported that coronary artery disease (CAD), which is a type of coronary heart disease, is the most prevalent heart condition. In 2022, it was responsible for 371,506 deaths. Approximately 5% of adults aged 20 and older are affected by CAD, which equates to about 1 in 20 individuals.
Continuous innovation in the design and material of coronary stents, such as bioresorbable stents and drug-eluting stents (DES), has improved their effectiveness and reduced complications like restenosis (re-narrowing of arteries). These advancements have significantly boosted their adoption in the market. In July 2024, MicroPort Scientific Corporation announced that its subsidiary, Shanghai MicroPort Medical, received NMPA approval for Firesorb, the world's first fully bioresorbable cardiac stent. Clinical studies show that Firesorb performs on par with permanent stents, with a 3-year target lesion failure rate of only 3.5% and a thrombosis rate of just 0.32%. Its superior endothelial coverage further distinguishes it from existing stents.
With improved healthcare infrastructure, better access to medical treatments, and greater awareness of coronary artery disease treatment options, more people seek stent-based interventions for heart-related issues, driving market growth. In December 2023, Terumo India introduced the Ultimaster Nagomi, a cutting-edge drug-eluting stent to treat coronary artery disease. This stent uses advanced technology to improve clinical outcomes and reduce restenosis rates. The Ultimaster Nagomi features a bioabsorbable polymer and a unique drug coating, designed to enhance healing and minimize complications, offering a promising solution for patients suffering from coronary artery blockages.
Detailed Segmentation:
Product Insights
The drug-eluting stents segment holds the highest market share of 82.3% in 2024. Drug-eluting stents (DES) are a significant advancement in coronary artery disease treatment, designed to reduce the risk of restenosis (re-narrowing of arteries) after stent implantation.
End Use Insights
The outpatient facilities segment holds the largest revenue share of 57.1% in 2024 in the coronary stents market. It is anticipated to grow at the fastest CAGR over the forecast period, primarily due to the growing trend of performing elective stent placements in less invasive settings. With advancements in stent technologies like drug-eluting stents and bioresorbable scaffolds, many coronary interventions can be safely performed in outpatient settings.
Regional Insights
The North America coronary stents industry is dominated the market with a 43.6% market share in 2024, driven by a high prevalence of cardiovascular diseases, advancements in medical technology, and a well-established healthcare infrastructure. The demand is fueled by a large aging population, growing healthcare awareness, and strong reimbursement policies. A March 2024 article in WIREs Nanomedicine and Nanobiotechnology discussed the significant role of nanotechnology in enhancing coronary stents, which had been vital in treating atherosclerosis.
Key Players of Coronary Stents Market
- Abbott
- Medtronic
- Boston Scientific Corporation
- Terumo Corporation
- B Braun SE
- Biotronik
- Stentys SA
- MicroPort Scientific Corporation
- R. Bard, Inc.
- Cook Medical
Recent Developments
- In September 2024, Uppsala University launched a flexible stent to reduce complications in coronary artery surgery. The Infinity-Swedeheart study, involving 2,400 patients from 20 Swedish hospitals, compared this new stent to the conventional Resolute Onyx stent. This innovation can potentially improve patient recovery and long-term success rates in cardiac surgery.
- In May 2024, Abbott launched the XIENCE Sierra Everolimus Eluting Coronary Stent System in India, enhancing treatment options for patients with blocked coronary arteries. This latest generation stent offers improved safety for complex cases and is part of Abbott's ongoing efforts to advance the angioplasty procedure, a minimally invasive method to restore blood flow to the heart using stents.
- In March 2024, Silk Road Medical, Inc., launched Tapered ENROUE Transcartoid Stent System in the U.S, primarily for the hospitals. Furthermore, the company’s CEO stated, “New tapered configurations for our ENROUTE Transcarotid Stent System build upon the robust portfolio of Silk Road’s carotid solutions. We are pleased to bring this portfolio expansion to market as part of our commitment to offering a diverse toolkit for physicians, allowing them to address individual patient anatomy
Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.
